14 January 2019 : Laboratory Research
Cimifugin Inhibits Inflammatory Responses of RAW264.7 Cells Induced by Lipopolysaccharide
Bin Han123ABCDF, Yuan Dai14ABC, Haiyan Wu3BC, Yuanyuan Zhang3DF, Lihong Wan3BF, Jianlei Zhao3CD, Yuanqi Liu3BCF, Shijun Xu14CEG*, Liming Zhou3AEDOI: 10.12659/MSM.912042
Med Sci Monit 2019; 25:409-417
Abstract
BACKGROUND: RAW264.7 cells are induced by lipopolysaccharide (LPS) as a rheumatoid arthritis (RA) model. The present study investigated the effect of cimifugin on the proliferation, migration, chemotaxis, and release of inflammation-related factors and inflammation-related signaling pathways of LPS-induced RAW264.7 cells.
MATERIAL AND METHODS: MTS assay was used to determine the proliferation of RAW264.7 cells. Transwell assay was employed to examine the migration and chemotaxis of the cells. ELISA was performed to measure the contents of chemotactic factors and inflammatory factors in cell culture supernatants. Western blotting was carried out to detect the expression of factors related with MAPKs and NF-κB signaling pathways.
RESULTS: Cimifugin (0–100 mg/L) had no cytotoxicity for RAW264.7 cells. LPS stimulation induced morphological differentiation of RAW264.7 cells, but intervention by cimifugin inhibited the activation effect by LPS by about 50%. Cimifugin (100 mg/L) decreased the migration and chemotaxis of RAW264.7 cells to 1/3 of that in control cells by decreasing the release of migration- and chemotaxis-associated factors by at least 30%. Cimifugin (100 mg/L) suppressed the release of inflammatory factors from RAW264.7 cells to less than 60% of that in the LPS group. In addition, cimifugin (100 mg/L) inhibited the activities of MAPKs and NF-κB signaling pathways.
CONCLUSIONS: The present study demonstrates that cimifugin reduces the migration and chemotaxis of RAW264.7 cells and inhibits the release of inflammatory factors and activation of related signaling pathways induced by LPS. Cimifugin may have potential pharmacological effects against RA.
Keywords: Cytokines, Felty syndrome, Anti-Inflammatory Agents, Arthritis, Rheumatoid, Chromones, Cyclooxygenase 2, Lipopolysaccharides, Macrophages, Models, Biological, Nitric Oxide, Nitric Oxide Synthase Type II, RAW 264.7 Cells
Editorial
01 July 2026 : Editorial
Editorial: The WHO Identifies Ebola Disease Due to Bundibugyo Virus as a Public Health Emergency of International Concern (PHEIC) as Vaccine Development AcceleratesDOI: 10.12659/MSM.954627
Med Sci Monit 2026; 32:e954627
In Press
Clinical Research
Synergistic Effects of AI-Driven Remote Respiratory Rehabilitation and Cervical Stabilization Exercises on ...Med Sci Monit In Press; DOI: 10.12659/MSM.952496
Clinical Research
Clinical Study of Clay Pot Combined With Thunder Fire Moxibustion in the Treatment of Chronic Refractory Wo...Med Sci Monit In Press; DOI: 10.12659/MSM.951574
Clinical Research
Body Weight and Insulin Resistance Indicators Among ChildrenMed Sci Monit In Press; DOI: 10.12659/MSM.951434
Clinical Research
Comparison of Radiographic Cervical Sagittal Alignment Parameters in Patients With Nonspecific Neck Pain, D...Med Sci Monit In Press; DOI: 10.12659/MSM.952950
Most Viewed Current Articles
17 Jan 2024 : Review article 14,175,412
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,756,504
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,465,935
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 708,619
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387






